DD01 Cut Liver Fat in 12 Weeks. Here's What the Phase 2 Trial Really Proved

A small phase 2 trial just produced a result that is hard to shrug off: after 12 weeks, 76% of people taking DD01 had reduced their liver fat by at least 30%. Only 12% of the placebo group reached the same mark.

That does not mean DD01 has reversed liver scarring, prevented cirrhosis, or earned a place in anyone’s current treatment plan. It does mean a liver-targeted GLP-1/glucagon drug moved one of the field’s most useful early markers quickly, in a randomized trial, with a large gap from placebo.

The catch is equally hard to miss. More than half of the DD01 group reported nausea. Nearly a third reported vomiting. Four of 33 participants stopped treatment because of adverse events.

So this is not another easy “next Ozempic” story. It is a promising liver study with a meaningful efficacy signal and a tolerability problem that the next round of data will need to answer.

The study in plain English

Researchers enrolled 67 adults at 12 US outpatient sites. Participants had obesity or overweight plus metabolic dysfunction-associated steatotic liver disease (MASLD) or its inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH). Fifty-two participants, or 78%, had MASH confirmed by biopsy.

The trial randomly assigned 33 people to once-weekly DD01 at 40 mg and 34 to placebo. Treatment was designed to run for 48 weeks, but the paper published in The Lancet Gastroenterology & Hepatology reports the prespecified 12-week analysis. The study was double-blind, and participants, investigators, assessors, study staff, and the sponsor were masked to treatment assignment.

The primary endpoint was not weight loss or a better liver-enzyme panel. It was the proportion of people who achieved at least a 30% relative reduction in liver fat measured by MRI proton density fat fraction, usually shortened to MRI-PDFF.

That threshold matters because a 30% MRI-PDFF reduction has been associated with better odds of histologic improvement in MASH. It is still a surrogate marker. An MRI can estimate fat accurately, but it cannot by itself prove that inflammation resolved or that fibrosis regressed.

At week 12, 25 of 33 people on DD01 reached the target, compared with four of 34 on placebo. The adjusted relative risk was 6.3, with a 95% confidence interval from 2.5 to 15.9. The p value was below 0.0001.

For an early trial, that is a clean separation. It is also based on 67 people and 12 weeks of observation. Both facts belong in the same sentence.

Why combine GLP-1 with glucagon?

DD01 activates the GLP-1 receptor and the glucagon receptor. That pairing may sound contradictory. GLP-1 medicines improve glucose control and reduce appetite. Glucagon is better known for raising blood glucose when the body needs fuel.

In a balanced dual agonist, the idea is to use GLP-1 signaling to control appetite and support insulin response while using glucagon signaling to increase energy expenditure and fat oxidation, particularly in the liver. DD01’s developers describe it as liver-targeted, which is central to the pitch: clear hepatic fat directly rather than relying only on weight loss to reduce the flow of fat into the liver.

This strategy is not unique to DD01. Survodutide, pemvidutide, and efinopegdutide also combine GLP-1 and glucagon activity in different proportions or molecular designs. Retatrutide adds GIP activity as a third target. Semaglutide and tirzepatide have also produced important MASH data through GLP-1 alone or GLP-1 plus GIP.

DD01’s result is interesting because of its speed and focus. Three out of four treated participants crossed the MRI-PDFF threshold by week 12. The trial authors called the reduction “rapid” and said it supports longer evaluation. That wording is appropriately restrained. The study shows a strong early liver-fat effect. It does not yet tell us whether DD01 improves fibrosis, which is far more closely tied to liver-related outcomes.

The side-effect bill was not small

Treatment-emergent adverse events occurred in 85% of the DD01 group and 68% of the placebo group. Nausea affected 18 of 33 people on DD01, or 55%, versus six of 34 on placebo. Vomiting occurred in 30% versus 12%, and diarrhea in 27% versus 18%.

Four DD01 participants, 12% of the treatment group, discontinued because of adverse events. One person in the placebo group did the same. The DD01 group also had two serious adverse events: abdominal pain and acute cholecystitis. The trial recorded no deaths.

A 40 mg dose with only two weeks of escalation may not be the final commercial strategy. Future studies could test a slower titration, different dose, or formulation. But that is a development hypothesis, not a reassurance. Right now, the published data show a potent liver-fat response alongside frequent gastrointestinal symptoms.

The safety numbers also come from too few people to characterize uncommon risks. A trial of 67 participants can reveal obvious tolerability trouble. It cannot settle questions about gallbladder disease, pancreatitis, cardiovascular effects, or rare adverse events.

What patients are noticing with today’s incretin drugs

DD01 is investigational, so there is no genuine user community taking an approved product. The closest anecdotes come from people using existing incretin medicines while living with fatty liver disease.

One r/Semaglutide commenter described biopsy and FibroScan concerns consistent with advanced fatty liver disease before taking oral semaglutide. After losing 50 pounds over a year, the user reported normalized liver enzymes and a follow-up FibroScan moving from an earlier F4 reading to F0-F1, with liver fat below 10%. They also disclosed taking vitamin E under a gastroenterologist’s direction. That confounder matters, as does the known tendency of inflammation and higher BMI to distort FibroScan estimates.

Another r/Semaglutide commenter wrote that their BMI fell from above 30 to 28 and that fatty-liver markers had resolved. The report was brief and did not include imaging, dates, or laboratory values.

These accounts were recovered from a public Reddit archive because Reddit’s live JSON interface was blocked during research. They are useful as a window into what patients watch: liver enzymes, imaging, weight, and access to treatment. They cannot tell us whether a drug repaired liver tissue, and they say nothing about DD01 itself.

What this means if you have MASLD or MASH

First, DD01 is not available for self-directed use. The registered phase 2 study, NCT06410924, is completed and no longer recruiting. No published result makes an unapproved research product safe to buy from a gray-market supplier.

Second, liver fat can change faster than liver fibrosis. A large MRI-PDFF improvement at 12 weeks is encouraging, but fibrosis is the slower and more consequential test. The full 48-week analysis should tell us more about inflammation, fibrosis, durability, weight, metabolic markers, and whether people can stay on treatment.

Third, the current treatment conversation is already moving. Lifestyle changes and weight reduction remain part of care. Resmetirom is available for selected adults with noncirrhotic MASH and moderate-to-advanced fibrosis. Semaglutide and other incretin therapies now have a growing liver evidence base, but eligibility, labeling, insurance coverage, and individual risk differ. A hepatologist or metabolic specialist can sort out which diagnosis is actually present and whether medication belongs in the plan.

Liver enzymes alone are not enough. People can have significant fibrosis with modest laboratory abnormalities, while enzymes can improve without proving that scarring has reversed. Clinical care may use fibrosis scores, elastography, MRI, and sometimes biopsy depending on risk.

The Oria take

DD01 deserves attention, but not because it has won the MASH race. It has earned a harder next question.

The efficacy signal is strong for an early, placebo-controlled study. A 64-point gap between treatment and placebo on the primary endpoint is substantial. The mechanism also makes biological sense in a field where clearing liver fat may require more than appetite suppression.

The weak points are just as specific: 67 participants, a sponsor-funded study, a 12-week surrogate endpoint, no proof yet of fibrosis improvement, and gastrointestinal adverse events common enough to affect persistence. DD01 may become a serious liver drug if the 48-week data connect early fat loss to tissue-level benefit without losing too many patients to nausea or vomiting.

Until then, the honest headline is neither “breakthrough” nor “failure.” DD01 cleared liver fat quickly in a well-designed small trial. Now it has to show that the improvement lasts, reaches the outcomes that matter, and can be tolerated outside a tightly managed study.

Evidence grade: B. Randomized, double-blind, placebo-controlled phase 2 data published in a Lancet specialty journal support a strong 12-week reduction in MRI-measured liver fat. The grade is limited by the small sample, short primary analysis, sponsor funding, surrogate endpoint, lack of reported fibrosis outcomes, and high gastrointestinal adverse-event rates.

Sources

1. Noureddin M, Dunn W, Patil R, et al. “The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02).” The Lancet Gastroenterology & Hepatology. 2026. DOI: https://doi.org/10.1016/S2468-1253(26)00130-5
2. PubMed record and abstract, PMID 42480572: https://pubmed.ncbi.nlm.nih.gov/42480572/
3. ClinicalTrials.gov, NCT06410924: https://clinicaltrials.gov/study/NCT06410924
4. Sanyal AJ, et al. “Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis.” New England Journal of Medicine. 2025. DOI: https://doi.org/10.1056/NEJMoa2413258
5. Loomba R, et al. “Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis.” New England Journal of Medicine. 2024. DOI: https://doi.org/10.1056/NEJMoa2401943
6. Reddit archive provenance: https://www.reddit.com/r/Semaglutide/comments/108fym5/rsrʃ_article_on_semaglutide_and_fatty_liver/j3s8yfy/ and https://www.reddit.com/r/Semaglutide/comments/10gcbot/anyone_getting_vilified/j53keaa/

Medical disclaimer: This article is for educational purposes only and is not medical advice. DD01 is investigational and is not approved for self-directed treatment. Do not buy or use unapproved research compounds. Diagnosis and treatment of MASLD or MASH should be guided by a qualified clinician using appropriate laboratory tests and imaging. Oria exists to help readers understand the evidence, not to replace individualized care.